Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

y has also won support from the Duchenne Parents Association and continues to work with them to progress this program through pre-clinical evaluation, in addition to the ongoing support from Agentschap NL (formerly SenterNovem).

GDNF

AMT is conducting pre-clinical research and has successfully completed a proof of concept study in a disease model of Parkinson's disease in collaboration with the University of Lund, Sweden. Data generated for AMT by the University of Wisconsin (USA) in a further pilot study using large animals also showed effective delivery, distribution and expression at levels that are expected to correlate with clinical efficacy; overcoming these challenges is one of the major challenges to clinical development. Taken together, these positive data encourage us to continue with the development of GDNF gene therapy and to extend it to other neurodegenerative indications such as multiple system atrophy (MSA) and Huntington's disease.

Sanfilippo B

Under an agreement signed at the beginning of this year, AMT is collaborating with a consortium led by Institut Pasteur in the clinical development of a novel gene therapy to treat Sanfilippo B. This rare genetic disease affecting new-born children leads to progressive neuronal degeneration and death. There is no approved therapy currently available.

On behalf of the Consortium, Institut Pasteur will lead the development program and will also sponsor the initial Phase I/II clinical study. AMT will manufacture and supply the adeno-associated virus, serotype 5 (AAV5) gene therapy product to the Consortium. The overall manufacturing contract entails payments to AMT of € 1.8 million. If the Consortium successfully demonstrates proof of concept in the Phase I/II study, AMT will have an option to acquire full commercial rights for the program. The Phase I/II clinical study is scheduled to begin in 2012.

Other Research and Development

AMT has demonstrated the ad
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... DC (PRWEB) July 28, 2014 It’s a ... GI Bill benefits to further their post-secondary education are failing ... a study released this year. And according to an analysis ... this shortfall is veteran students’ uninformed choice of college majors, ... The details of the study: Some 51.7 percent of post-9/11 ...
(Date:7/28/2014)... 28, 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... is a technique used to determine the size of a ... is crucial to analyze the size of particles as it ... analysis is performed to determine the behavior and nature of ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... estimated at USD 161,056.5 million in 2014 and is ... 2014 to 2020, to reach an estimated value of ... market is witnessing a significant growth due to the ...
Breaking Biology Technology:Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... /PRNewswire-Asia-FirstCall/  - China Cord Blood Corporation (NYSE: ... largest cord blood banking operator in China, today announced ... which allowed warrant holders to receive one ordinary share ... ordinary shares, equivalent to 2.2% of shares outstanding as ...
... BioTrends Research Group, Inc. finds that with ... (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate ... month after the launch of Gilenya, trial and uptake of ... to be tempered due to the perception that Extavia is ...
... December 9, 2010 Scientists from Pacific Biosciences of ... successfully employed single molecule, real-time (SMRT) DNA sequencing technology ... deadly cholera epidemic in Haiti. Published Thursday in ... results provide the first whole genome sequence analysis and ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of Warrant Exchange 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 2Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 3
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
(Date:7/27/2014)... 18,000 patients, scientists have identified more than two ... including six that had not been previously reported. ... was partially funded by the National Institutes of ... NIH laboratories. , "Unraveling the genetic underpinnings of ... involved in this complex disease, and hopefully, may ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
... laser laboratory operational later this year, he will use ... bonds like a stringed musical instrument. Tokmakoff, the ... at the University of Chicago in January to tackle ... vibrational spectroscopy methods that he has developed. "He ...
... Cognitive impairments are disabling for individuals with schizophrenia, ... affect a wide range of cognition, including memory, ... appear in the earliest stages of the disease ... Scientists are exploring a variety of strategies ...
... 2013 Shiner Beers, the popular Texas craft brew, will ... for Diabetes Research at the Translational Genomics Research Institute (TGen). ... kick off on Wednesday, March 13, at the Hotel San ... Conferences & Festivals. The noon-8 p.m. event, themed after ...
Cached Biology News:Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3Tickling the brain with magnetic stimulation improves memory in schizophrenia 2Shiner Beers launches nationwide support of TGen diabetes studies 2
... Dithiothreitol DTT White solid.. ... disulfides to thiols, so reaction is "driven" to ... not contain waxy surfactant found in many other ... pentobarbitol. Purity: ≥97% by titration. ...
... This kit is designed for easy transformation ... protocol allows for successful transformation simply by ... reagents with cultured yeast cells. No complicated ... are required. The kit is particularly well ...
... for easy transformation of the budding yeast, ... transformation simply by mixing a plasmid DNA ... cells. No complicated steps, such as centrifugation ... is particularly well suited for high-throughput transformation ...
... pro balance increases your lab productivity and allows ... and regulatory compliance. Move ahead beyond traditional paper-based ... data system. *Instruments supported: ... MX, UMX, AG, XS, XP, PR, SR, PG-S, ...
Biology Products: